Lunai Bioworks Inc (LNAI) Financiero

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 29 full-time employees. The company went IPO on 2014-11-18. The company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. Its segments include RENB, BioSymetrics and RENC. The RENB segment is engaged in developing new immunotherapies to combat cancer. BioSymetrics is engaged in integrating multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to advance biomarker discovery, therapeutic development, and precision medicine. RENC is developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform.